An Open-Label Phase II Study of Relatlimab (BMS-986016) With Nivolumab (BMS-936558) in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients
Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies before allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment- naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy